Compare Merck & Co., Inc. (MRK) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NextEra Energy, Inc. — how do they compare? Merck & Co., Inc. trades at $146.19 (market cap $351.28B), while NextEra Energy, Inc. trades at $77.4 (market cap $161.39B). The key difference: Merck & Co., Inc. is far larger — about 2.2× NextEra Energy, Inc.'s market cap, and NextEra Energy, Inc. pays the higher dividend (3.22%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NextEra Energy, Inc. for 83 Days on average.
| MRK | NEE | |
|---|---|---|
Market Cap | $351.28B | $161.39B |
Volume | 7,969,665 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $156.43 | $97.88 |
52-Week Low | $82.49 | $75.49 |
Typical Hold Time | 98 Days | 83 Days |
Enterprise Value | $398.04B | $268.72B |
Dividend Yield | 2.39% | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
NextEra Energy (NEE) trades at $77.34, up 0.36% on the day, with a bearish technical signal but strong analyst support. The stock is near a 52-week low, with key support at $76. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains robust profitability with a 32.4% net margin and is pursuing growth through projects like the $22.3 billion Project Star energy campus.
The outlook is cautiously optimistic, with a consensus price target of $96 offering 24% upside. Risks include high debt levels and interest rate sensitivity, but strong cash flow and a 66.7% buy rating from analysts suggest long-term value. Investors should weigh growth initiatives against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
